Ulcerative colitis (UC) is a chronic inflammatory disease that causes ongoing immune-driven damage to the lining of the colon. People living with UC for many years face a significantly higher risk of developing colorectal cancer (CRC) compared to the general population. This elevated risk means that regular cancer surveillance is a critical part of long-term care for UC patients.
Cancer in UC patients, known as UC-associated neoplasia (UCAN), arises through a process driven by chronic inflammation and specific genetic changes, particularly involving the p53 tumor suppressor gene. This pathway differs from how sporadic (non-UC) colorectal cancers develop, and it tends to produce lesions with distinctive and often challenging visual characteristics.
Unlike the raised polyps typically seen in sporadic colon cancer, UCAN lesions are frequently flat or non-polypoid, making them difficult to spot even with careful examination. Chronic inflammation in the colon can further obscure these lesions, complicating surveillance efforts. As more patients live longer with UC thanks to improved medical treatments, finding reliable ways to detect UCAN earlier has become increasingly important.
The current standard for UC cancer surveillance is colonoscopy with chromoendoscopy, a technique that applies a dye to the colon lining to highlight subtle surface changes. While colonoscopy remains the gold standard, there is growing interest in understanding whether non-invasive imaging tools like computed tomography colonography (CTC) could play a complementary role, especially for patients who cannot safely undergo endoscopy.
Computed tomography colonography (CTC), sometimes called virtual colonoscopy, is a non-invasive imaging test that uses a CT scanner to create detailed three-dimensional images of the colon. Unlike traditional colonoscopy, it does not require inserting a flexible scope into the colon, making it a useful option for patients with obstructions, strictures, or other conditions that prevent complete endoscopic evaluation.
CTC is well-established as a screening tool for sporadic colorectal cancer, where lesions typically appear as raised polyps that are relatively easy to identify on imaging. However, its usefulness in UC patients has not been thoroughly studied. Current European guidelines only recommend CTC in UC patients when endoscopy is blocked by a stricture (a narrowing of the bowel), primarily to assess inflammation rather than to look for cancer.
As the UC patient population ages and grows, more people may undergo CTC in routine clinical practice, even outside the guideline recommendations. This creates an important need to understand exactly what UCAN looks like on CT imaging, and when CTC can and cannot reliably detect it. Without this knowledge, radiologists may miss lesions or misinterpret inflammatory changes as cancer.
This study, conducted at Keio University Hospital in Tokyo, Japan, aimed to fill this evidence gap by systematically comparing CTC findings to endoscopic and pathological results in a group of UC patients known to have neoplastic lesions. It is the first study to evaluate CTC detectability of UCAN in a structured, retrospective analysis across a defined patient cohort.
The researchers conducted a single-center, retrospective observational study at Keio University Hospital, enrolling 50 patients with confirmed UC who underwent preoperative CTC before scheduled pancolectomy (complete surgical removal of the colon) for UCAN between January 2014 and June 2024. In total, 71 histologically confirmed neoplastic lesions were analyzed. Six patients were excluded due to prior endoscopic resection or being deemed inoperable.
The CTC procedure followed a standardized protocol. Patients underwent bowel preparation the day before, then had carbon dioxide gas introduced into the colon via a rectal catheter. CT images were taken in both prone and supine positions using high-resolution multidetector scanners, allowing the bowel walls to be examined from multiple angles. Non-contrast images were combined with contrast-enhanced scans to improve lesion visibility.
Image interpretation was performed by two experienced radiologists, each with a minimum of 1,000 prior CTC readings, who were aware that lesions existed but assessed whether each individual lesion was identifiable on the CT scan. Their findings were then independently validated by two expert IBD endoscopists who compared CTC images to the original colonoscopy findings. This awareness design specifically tests the limits of CTC even under ideal conditions.
Lesion characteristics were carefully recorded, including size, location, endoscopic morphology (sessile, superficial elevated, flat, depressed, or advanced cancer type), and histopathologic invasion depth. Statistical analyses used logistic regression to identify which factors were independently associated with CTC detectability, accounting for potential confounding variables like disease extent and inflammation severity.
Of the 71 neoplastic lesions in the study, only 49% (35 out of 71) were detectable by CTC. This means that despite the radiologists knowing in advance that lesions existed, more than half of all confirmed cancer lesions were invisible on the CT scan. This finding highlights a fundamental limitation of CTC for UC-associated neoplasia surveillance.
Detection varied significantly based on lesion morphology. The highest detection rates were seen in lesions with more obvious physical structure: advanced cancer types (100%, 7/7), sessile lesions (80%, 4/5), and depressed lesions (80%, 8/10). These lesion types protrude or create visible contour changes that CT can capture. In contrast, flat lesions, the most common UC morphology, were detected only 8% of the time (2 out of 25).
Detection also varied by depth of tumor invasion. Lesions confined to the innermost layer of the colon wall (intramucosal) were detected only 29% of the time (12/42). Detection improved with deeper invasion: 75% for submucosal, 100% for muscularis propria (the muscle layer), and 73% for subserosal invasion. This pattern makes intuitive sense since deeper lesions cause more visible changes to the colon wall architecture.
An unexpected finding was that three lesions with subserosal invasion, which represents an advanced cancer stage, were missed on CTC. On retrospective review, these lesions appeared as subtle, asymmetric sclerotic (scarring-like) wall thickening without obvious elevation. This is a UCAN-specific imaging pattern not seen in sporadic colorectal cancers, suggesting that even experienced radiologists trained in sporadic cancer may miss advanced UCAN.
To understand what makes a lesion invisible on CTC, the researchers performed both simple (univariable) and adjusted (multivariable) logistic regression analyses. These statistical models identified which lesion characteristics were independently associated with failure to detect a lesion, even after accounting for other factors like patient age, disease duration, and inflammation severity.
The analysis identified two strong, independent predictors of non-detection. First, flat morphology was associated with a dramatically reduced chance of detection, with an adjusted odds ratio of 0.06. This means flat lesions were approximately 94% less likely to be detected on CTC compared to superficial elevated lesions. Of the 25 flat lesions in the study, 23 (92%) were confined to the mucosa, reflecting the close relationship between flat morphology and early invasion depth.
Second, intramucosal invasion (cancer confined to the innermost lining of the colon) independently predicted non-detection with an adjusted odds ratio of 0.10, meaning intramucosal lesions were 90% less likely to be detected compared to submucosal lesions. Separately modeling morphology and depth was necessary because these two characteristics were highly correlated with each other, which could skew statistical results if analyzed together.
Interestingly, inflammation level as measured by the Mayo endoscopic subscore (MES) showed a trend toward lower detection in patients with milder inflammation (MES 0 or 1), but this did not reach statistical significance. The researchers note that higher detection rates in actively inflamed patients likely reflect selection bias, where only the most visible and elevated lesions remain detectable despite surrounding inflammation, rather than CTC performing better in active disease.
The most important clinical message from this study is that endoscopy cannot be replaced by CTC for cancer surveillance in UC patients. Even with expert radiologists who knew where to look, CTC missed approximately half of all neoplastic lesions. For flat-type lesions, which represent the most common UCAN morphology, CTC failed to detect 92% of cases. This is not a matter of technique or technology limitations that can easily be overcome; it reflects the fundamental nature of how UCAN grows in the colon wall.
However, CTC may still have a role in specific situations. The study showed that advanced cancers were detected 100% of the time, and lesions with deeper invasion into the colon wall were also reliably visible. For patients who cannot safely undergo colonoscopy, such as those with severe strictures, very elderly patients, or those with significant comorbidities, CTC may provide useful information about more advanced lesions while endoscopy is being planned or considered.
A novel finding with important clinical implications is the identification of a unique UCAN-specific imaging pattern on CTC: asymmetric sclerotic wall thickening without visible elevation, seen in some advanced subserosal lesions. Radiologists trained primarily on sporadic colon cancer may not recognize this pattern and could miss these advanced cases. Education about UCAN-specific CT findings is needed to improve diagnostic accuracy when CTC is used in UC patients.
For families and patients, the key takeaway is that regular colonoscopy surveillance remains essential if you have long-standing UC. CT colonography should not be viewed as a substitute for colonoscopy. If your doctor recommends routine surveillance endoscopy, following through with those appointments is the most reliable way to detect early-stage UC-associated neoplasia when it is most treatable.
The study authors acknowledge several important limitations. It was a single-center retrospective study with a relatively small sample of 50 patients over 10 years, conducted at a specialized academic center in Japan. The findings may not fully generalize to community hospitals or to populations with different UC characteristics. The absence of a control group also prevented calculation of traditional diagnostic metrics like sensitivity and specificity from a surveillance perspective.
Critically, all patients in this study had already been confirmed to have UCAN through prior colonoscopy, representing a very high-risk, pre-selected population. Real-world surveillance would involve a much lower proportion of individuals actually having cancer, which would affect the predictive value of CTC. The study was therefore best suited to characterize CTC findings in known UCAN rather than to assess its utility as a screening tool in unselected populations.
Another challenge identified was the difficulty distinguishing inflammatory polyps from neoplastic lesions on CTC. Inflammatory polyps, which do not progress to cancer, can appear elevated on CT scans and mimic dysplastic growths. Without additional endoscopic confirmation, CT images alone cannot reliably determine which elevated areas represent true neoplasia, further limiting CTC's standalone diagnostic accuracy in UC patients.
Looking forward, the authors suggest that the unique CT imaging patterns of UCAN, particularly the sclerotic wall changes seen in advanced subserosal lesions, could be incorporated into AI-based detection systems or radiologist education programs to improve diagnostic yield. Future multicenter studies with larger patient populations are needed to validate these imaging patterns and to explore whether emerging CT technologies might improve detection rates for flat and early-stage UCAN.
This study is the first systematic evaluation of CTC for detecting UC-associated neoplasia, and its findings are unambiguous: CTC has substantial limitations for UCAN surveillance. Overall, it detected only 49% of known lesions. For the flat lesions that comprise a major portion of UCAN, detection dropped to just 8%. Even with advance knowledge of lesion locations, experienced radiologists could not reliably identify these early-stage cancers on CT imaging.
The two strongest predictors of CTC failure were flat morphology and intramucosal invasion depth. These characteristics are not random; they represent the most common and earliest forms of UCAN, precisely the cancers that would benefit most from early detection. The limitations of CTC are therefore most significant exactly when the potential clinical benefit would be greatest.
Despite these limitations, CTC may serve a complementary role in selected situations, particularly for detecting advanced cancers, evaluating patients with strictures that block endoscopic access, or assessing extraluminal disease spread. The discovery of UCAN-specific imaging patterns, such as asymmetric sclerotic thickening in subserosal lesions, opens a path for improving radiologist training and potentially AI-assisted detection.
Ultimately, this research reinforces that for patients with ulcerative colitis, endoscopic surveillance with chromoendoscopy remains the cornerstone of cancer detection. The clinical implication is clear: CTC should not replace colonoscopy for cancer surveillance in UC, and any future role for CTC in this setting requires further research before it can be routinely recommended.